FrancophonIA/ELRC3.0 huggingface dataset:
English: It is used as maintenance (regular) treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Slovenian: Uporablja se kot vzdrževalno (redno) zdravljenje za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
English: The full EPAR and risk management plan summary for Ulunar Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Ulunar Breezhaler sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ulunar Breezhaler on 23 April 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Ulunar Breezhaler, veljavno po vsej Evropski uniji, odobrila dne 23. aprila 2014.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Ulunar Breezhaler's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ulunar Breezhaler večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: In both studies, the main measure of effectiveness was how Ulunar Breezhaler improved patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
Slovenian: V obeh študijah je bilo glavno merilo učinkovitosti bolnikovo izboljšanje forsiranega ekspiracijskega volumna (FEV1 - največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) po 26 tednih zdravljenja.
English: Ulunar Breezhaler has been studied in two main studies involving a total of 2,667 patients with COPD.
Slovenian: Zdravilo Ulunar Breezhaler so proučevali v dveh glavnih študijah, v kateri je bilo skupaj vključeno 2 667 bolnikov s KOPB.
English: This is a summary of the European public assessment report (EPAR) for Ulunar Breezhaler.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ulunar Breezhaler.
English: The combined action of the two active substances helps to keep the airways open and allows the patient to breathe more easily.
Slovenian: Kombinirano delovanje obeh zdravilnih učinkovin pomaga vzdrževati prehodnost dihal in bolniku olajša dihanje.
English: The most common side effects with Ulunar Breezhaler (which may affect more than 1 in 10 people) are upper respiratory tract infections (colds).
Slovenian: Najpogostejši neželeni učinki zdravila Ulunar Breezhaler (ki prizadenejo več kot 1 osebo od 10) so okužbe zgornjih dihal (prehladi).
English: Ulunar Breezhaler is a medicine that contains two active substances, indacaterol (85 micrograms) and glycopyrronium (43 micrograms).
Slovenian: Ulunar Breezhaler je zdravilo, ki vsebuje dve zdravilni učinkovini, indakaterol (85 mikrogramov) in glikopironij (43 mikrogramov).
English: It is taken at the same time each day using the Ulunar Breezhaler device.
Slovenian: Jemlje se vsak dan ob istem času z uporabo inhalatorja Ulunar Breezhaler.
English: Glycopyrronium is a muscarinic receptor antagonist.
Slovenian: Glikopironij je antagonist muskarinskih receptorjev.
English: In patients with severely reduced kidney function Ulunar Breezhaler should only be used after a careful benefit-risk assessment.
Slovenian: Pri bolnikih s hudo prizadetim delovanjem ledvic se sme zdravilo Ulunar Breezhaler uporabiti samo po skrbni oceni razmerja med tveganji in koristmi.
English: What measures are being taken to ensure the safe and effective use of Ulunar Breezhaler?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ulunar Breezhaler?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ulunar Breezhaler, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Ulunar Breezhaler vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: A risk management plan has been developed to ensure that Ulunar Breezhaler is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Ulunar Breezhaler je bil pripravljen načrt obvladovanja tveganj.
English: For more information about treatment with Ulunar Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Ulunar Breezhaler preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Other information about Ulunar Breezhaler
Slovenian: Druge informacije o zdravilu Ulunar Breezhaler
English: Ulunar Breezhaler is available as capsules containing a powder for inhalation and can only be obtained with a prescription.
Slovenian: Zdravilo Ulunar Breezhaler je na voljo v obliki kapsul, ki vsebujejo prašek za inhaliranje, in se izdaja le na recept.
English: COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
Slovenian: Kronična obstruktivna pljučna bolezen je dolgotrajna bolezen, pri kateri so dihalne poti in pljučni mešički poškodovani ali blokirani, kar povzroča oteženo vdihavanje in izdihavanje zraka.
English: The effects of Ulunar Breezhaler when used to relieve symptoms of COPD were clinically meaningful.
Slovenian: Pri uporabi zdravila Ulunar Breezhaler za lajšanje simptomov KOPB so bili njegovi učinki klinično pomembni.
English: The company that makes Ultibro Breezhaler has agreed that its scientific data can be used for Ulunar Breezhaler (‘informed consent').
Slovenian: Družba, ki izdeluje zdravilo Ultibro Breezhaler, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Ulunar Breezhaler („uporaba dokumentacije s soglasjem“).
English: What is Ulunar Breezhaler and what is it used for?
Slovenian: Kaj je zdravilo Ulunar Breezhaler in za kaj se uporablja?
English: A third study investigated the effects of Ulunar Breezhaler on the rate of exacerbations (flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium (other treatments for COPD).
Slovenian: V tretji študiji so proučevali učinke zdravila Ulunar Breezhaler na število poslabšanj (izbruhov bolezni), ki so se pri bolnikih pojavili v 64 tednih zdravljenja, v primerjavi z zdravljenjem z glikopironijem ali tiotropijem (drugima oblikama zdravljenja KOPB).
English: Ulunar Breezhaler indacaterol / glycopyrronium
Slovenian: Ulunar Breezhaler indakaterol/glikopironij
English: The reduction in the rate of exacerbations was 10 to 12% higher with Ulunar Breezhaler than with tiotropium and glycopyrronium.
Slovenian: Zmanjšanje števila poslabšanj je bilo pri zdravilu Ulunar Breezhaler za 10 do 12 % večje kot pri tiotropiju in glikopironiju.
English: Regarding its safety, Ulunar Breezhaler is comparable to indacaterol and glycopyrronium used as separate medicines.
Slovenian: Varnost zdravila Ulunar Breezhaler je primerljiva z indakaterolom in glikopironijem, uporabljenima kot ločeni zdravili.
English: The first study showed that treatment with Ulunar Breezhaler was more effective than placebo and increased FEV1 by an average of 200 ml more.
Slovenian: Prva študija je pokazala, da je bilo zdravljenje z zdravilom Ulunar Breezhaler učinkovitejše od placeba, saj je bila vrednost FEV1 v povprečju za 200 ml večja kot pri placebu.
English: The active substances in Ulunar Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD.
Slovenian: Zdravilni učinkovini v zdravilu Ulunar Breezhaler, indakaterol in glikopironij, različno razširita dihalne poti in izboljšata dihanje pri bolnikih s KOPB.
English: For practical information about using Ulunar Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Ulunar Breezhaler naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: What benefits of Ulunar Breezhaler have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Ulunar Breezhaler izkazalo v študijah?
English: Ulunar Breezhaler also increased FEV1 by 70 ml more than indacaterol alone and 90 ml more than glycopyrronium alone.
Slovenian: Zdravilo Ulunar Breezhaler je prav tako povečalo vrednost FEV1 za dodatnih 70 ml v primerjavi z indakaterolom kot samostojnim zdravilom in za 90 ml v primerjavi z glikopironijem kot samostojnim zdravilom.
English: While one study compared the effects of Ulunar Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ulunar Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Slovenian: V eni študiji so primerjali učinke zdravila Ulunar Breezhaler z učinki placeba (zdravila brez zdravilne učinkovine) ali zgolj indakaterola oziroma glikopironija, v drugi pa zdravilo Ulunar Breezhaler s kombinacijo flutikazona in salmeterola, tj. standardno obliko zdravljenja KOPB.
English: In the second study the average increase in FEV1 was 140 ml more with Ulunar Breezhaler treatment than with treatment with fluticasone and salmeterol.
Slovenian: V drugi študiji je bila vrednost FEV1 pri zdravilu Ulunar Breezhaler v povprečju za 140 ml večja kot pri uporabi flutikazona in salmeterola.
English: Muscarinic receptor antagonists and long-acting beta-2 agonists are commonly combined in the management of COPD.
Slovenian: Kombinacija antagonistov muskarinskih receptorjev in dolgodelujočih agonistov beta-2 adrenergičnih receptorjev se pogosto uporablja za uravnavanje KOPB.
English: What are the risks associated with Ulunar Breezhaler?
Slovenian: Kakšna tveganja so povezana z zdravilom Ulunar Breezhaler?
English: Why is Ulunar Breezhaler approved?
Slovenian: Zakaj je bilo zdravilo Ulunar Breezhaler odobreno?
English: How is Ulunar Breezhaler used?
Slovenian: Kako se zdravilo Ulunar Breezhaler uporablja?
English: It is not intended to provide practical advice on how to use Ulunar Breezhaler.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: How does Ulunar Breezhaler work?
Slovenian: Kako zdravilo Ulunar Breezhaler deluje?
English: This summary was last updated in 1-2006 ©EMEA 2006
Slovenian: Ta povzetek je bil nazadnje posodobljen 1-2006.©EMEA 2006
English: Other information about Monotard:
Slovenian: Druge informacije o zdravilu Monotard:
English: In type 1 diabetes, the dosage varies between 0.5 and 1.0 IU/kg (0.7 and 1.0 IU/kg in children before puberty), in type 2 diabetes the dosage is 0.3 to 0.6 IU/kg.
Slovenian: Pri sladkorni bolezni tipa 1 se odmerek giblje med 0,5 in 1,0 IU/kg (0,7 in 1,0 IU/kg pri predpubertetnih otrocih), pri sladkorni bolezni tipa 2 pa znaša odmerek med 0,3 do 0,6 IU/kg.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Monotard to Novo Nordisk A/S in on 7 October 2002.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Monotard, veljavno po vsej Evopski uniji, odobrila družbi Novo Nordisk A/S dne 7. oktobra 2002.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MONOTARD EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) MONOTARD Povzetek EPAR za javnost
English: If convenient it may also be given in the abdominal wall (tummy), the buttocks or the deltoid region (shoulder).
Slovenian: Če je primerno, se lahko daje tudi v abdominalno steno (trebuh), zadnjico ali predel deltoidne mišice (rame).
English: Monotard is a long-acting insulin, it can be given as a once daily or twice daily injection, with or without a fast-acting insulin (at meal times), according to the doctor's recommendation.
Slovenian: Zdravilo Monotard je insulin z dolgotrajnim delovanjem in ga lahko dajemo z injekcijo enkrat ali dvakrat dnevno z ali brez insulina s hitrim delovanjem (v času obroka) v skladu s priporočili zdravnika.
English: The studies measured the level of fasting blood sugar or a substance (glycosylated haemoglobin, HbA1c), which gives an indication of how well the blood sugar is controlled.
Slovenian: V raziskavah so merili raven sladkorja v krvi na tešče ali tiste snovi v krvi (glikoziliranega hemoglobina, HbA1c), ki nam pokaže, kako dobro je raven sladkorja v krvi nadzorovana.
English: The Committee for Medicinal products for Human Use (CHMP) decided that Monotard's benefits are greater than its risks for the treatment of diabetes.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Monotard pri zdravljenju sladkorne bolezni večje od z njim povezanih tveganj.
English: What benefit has Monotard shown during the studies?
Slovenian: Kakšne koristi je zdravilo Monotard izkazalo med raziskavami?
English: The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Slovenian: Nadomestni insulin deluje na enak način kot naravno proizveden insulin in omogoča, da lahko glukoza vstopi iz krvi v celico.
English: Monotard should not be used in people who may be hypersensitive (allergic) to insulin human (rDNA) or to any of the other ingredients.
Slovenian: Zdravila Monotard ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) človeški insulin (rDNA) ali katero koli drugo sestavino.
English: Monotard has been studied in both type 1 and type 2 diabetes, and it has been compared to other types of insulin (porcine, human).
Slovenian: Zdravilo Monotard so raziskali tako za sladkorno bolezen tipa 1 kot tudi tipa 2 in ga primerjali z drugimi vrstami insulina (prašičjim, človeškim).
English: Monotard doses might also need to be adjusted when given with a number of other medicines which may have an effect on blood sugar (the full list is available in the Package Leaflet).
Slovenian: Odmerke zdravila Monotard bo morda potrebno prilagoditi, če se zdravilo jemlje istočasno s številnimi drugimi zdravili, ki vplivajo na koncentracijo sladkorja v krvi (celoten seznam le-teh najdete v Navodilih za uporabo).
English: What is the risk associated with Monotard?
Slovenian: Kakšna tveganja so povezana z zdravilom Monotard?
English: Monotard can be used in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin effectively.
Slovenian: Lahko se uporablja za zdravljenje sladkorne bolezni tipa 1, pri kateri trebušna slinavka ne more tvoriti insulina, in sladkorne bolezni tipa 2, pri kateri telo insulina ni zmožno učinkovito uporabiti.
English: Monotard is used in patients with diabetes mellitus.
Slovenian: Zdravilo Monotard se uporablja za bolnike s sladkorno boleznijo.
English: Monotard is an insulin suspension for injection.
Slovenian: Zdravilo Monotard je suspenzija insulina za injiciranje.
English: Monotard was effective for both Type 1 and Type 2 diabetes.
Slovenian: Zdravilo Monotard se je izkazalo kot učinkovito tako za sladkorno bolezen tipa 1 kot tudi tipa 2.
English: Why has Monotard been approved?
Slovenian: Zakaj je bilo zdravilo Monotard odobreno?
English: Monotard may cause hypoglycaemia (low blood sugar).
Slovenian: Zdravilo Monotard lahko povzroči hipoglikemijo (nizko koncentracijo sladkorja v krvi).
English: Monotard is supplied as 40 or 100 IU strengths in vials.
Slovenian: Monotard je na voljo v vialah jakosti 40 ali 100 mednarodnih enot (IU).
English: Monotard contains insulin mixed with another substance, zinc, in particles from which the insulin is absorbed much more slowly during the day; and this gives Monotard a longer duration of action.
Slovenian: Zdravilo Monotard vsebuje insulin, pomešan z drugo snovjo, in sicer z delci cinka, iz katerega se insulin tekom dneva absorbira mnogo počasneje, kar podaljša čas delovanja zdravila Monotard.
English: They recommended that Monotard be given marketing authorisation.
Slovenian: Zato je priporočil, da se za zdravilo Monotard podeli dovoljenje za promet z zdravilom.
English: Monotard led to a decrease in the level of HbA1c, indicating that blood sugar levels had been controlled to a similar level to that seen with other human insulin.
Slovenian: Z uporabo zdravila Monotard se je znižala raven HbA1c, kar kaže na to, da je bila raven sladkorja v krvi vzdrževana na podobnih ravneh kot pri uporabi drugih vrst človeškega insulina.
English: The full EPAR for Monotard is available here.
Slovenian: Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Monotard je na voljo tukaj.
English: Monotard contains the active ingredient insulin human (rDNA).
Slovenian: Zdravilo Monotard vsebuje zdravilno učinkovino človeški insulin (rDNA).
English: How has Monotard been studied?
Slovenian: Kako je bilo zdravilo Monotard raziskano?
English: Monotard is given subcutaneously (under the skin) by injection, usually in the thigh.
Slovenian: Zdravilo Monotard se daje s subkutano (podkožno) injekcijo, navadno v stegno.
English: For the full description of the side effects reported with Monotard, please see the Package Leaflet.
Slovenian: Celovit opis neželenih učinkov, o katerih so poročali pri uporabi zdravila Monotard, najdete v Navodilih za uporabo.
English: Monotard is a replacement insulin which identical to the insulin made by the pancreas .The active ingredient of Monotard, insulin human (rDNA), is produced by a method known as ‘recombinant technology'.
Slovenian: Zdravilno učinkovino zdravila Monotard, človeški insulin (rDNA), izdelujejo z metodo, znano pod imenom “rekombinantna tehnologija”.
English: What is Monotard used for?
Slovenian: Za kaj se zdravilo Monotard uporablja?
English: How is Monotard used?
Slovenian: Kako se zdravilo Monotard uporablja?
English: What is Monotard?
Slovenian: Kaj je zdravilo Monotard?
English: How does Monotard work?
Slovenian: Kako zdravilo Monotard deluje?
English: (EU) MA Number Invented name
Slovenian: EU(MA) številka
English: Further information on Slenyto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Slenyto so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The doctor should review treatment regularly, at least every 6 months, and only continue treatment if the patient is benefits from it.
Slovenian: Zdravnik mora redno, vsaj vsakih šest mesecev, pregledovati zdravljenje in ga nadaljevati le, če bolniku koristi.
English: The side effects seen with the medicine over 2 years appear mild or moderate but more data are needed on longer term safety.
Slovenian: Neželeni učinki, ki so jih opazili pri zdravilu v dveh letih, so blagi ali zmerni, vendar je potrebnih več podatkov o dolgoročni varnosti.
English: What measures are being taken to ensure the safe and effective use of Slenyto?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Slenyto?
English: Slenyto is available as tablets (1 and 5 mg).
Slovenian: Zdravilo Slenyto je na voljo v obliki tablet (1 in 5 mg).
English: The European Medicines Agency decided that Slenyto's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Slenyto večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Why is Slenyto authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Slenyto odobreno v EU?
English: Its levels in the blood normally increase after the onset of darkness and peak in the middle of the night.
Slovenian: Njegove ravni v krvi se običajno povečajo, ko se začne temniti, in vrhunec dosežejo sredi noči.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Slenyto have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Slenyto upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have:
Slovenian: Slenyto je zdravilo za zdravljenje nespečnosti (težav s spanjem) pri otrocih in mladostnikih (starih od dveh do 18 let), ki imajo:
English: The medicine contains the active substance melatonin.
Slovenian: Zdravilo vsebuje učinkovino melatonin.
English: What are the risks associated with Slenyto?
Slovenian: Kakšna tveganja so povezana z zdravilom Slenyto?
English: What is Slenyto and what is it used for?
Slovenian: Kaj je zdravilo Slenyto in za kaj se uporablja?
English: Side effects reported with Slenyto are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Slenyto, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: The normal dose is 2 mg taken 30 minutes to one hour before bedtime.
Slovenian: Običajni odmerek je 2 mg, ki ga bolnik vzame 30 minut do eno uro pred spanjem.
English: • Smith-Magenis syndrome, a condition that can lead to learning difficulties.
Slovenian: • sindrom Smith-Magenis, tj. stanje, ki lahko povzroča učne težave.
English: • autism spectrum disorder (ASD), a range of conditions that affects the patient's social interactions;
Slovenian: • motnjo avtističnega spektra (ASD), tj. različna stanja, ki vplivajo na bolnikove socialne stike,
English: An overview of Slenyto and why it is authorised in the EU
Slovenian: Pregled zdravila Slenyto in zakaj je odobreno v EU
English: All patients had previously tried other measures, such as keeping to a regular sleeping routine, which did not work.
Slovenian: Vsi bolniki so predhodno že preizkusili druge ukrepe, kot so redna spalna rutina, vendar niso učinkovali.
English: For more information about using Slenyto, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Slenyto glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Patients with developmental conditions may produce less melatonin, leading to the development of insomnia.
Slovenian: Bolniki z razvojnimi težavami lahko tvorijo manj melatonina, kar privede do nespečnosti.
English: Melatonin is involved in coordinating the body's sleep cycle by acting on cells in specific areas of the brain and helping to bring about sleep.
Slovenian: Melatonin sodeluje pri usklajevanju spalnega cikla telesa, tako da deluje na celice v določenih predelih možganov in pomaga pri uspavanju.
English: As for all medicines, data on the use of Slenyto are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Slenyto stalno spremljajo.
English: The most common side effects with Slenyto (which may affect up to 1 in 10 people) are sleepiness, tiredness, mood swings, headache, irritability, aggression and feeling hungover.
Slovenian: Najpogostejši neželeni učinki zdravila Slenyto (ki se lahko pojavijo pri največ 1 od 10 bolnikov) so zaspanost, utrujenost, nihanja razpoloženja, glavobol, razdražljivost, agresivnost in občutek, podoben občutku po prekomernem zaužitju alkohola.
English: In addition, children who took Slenyto fell asleep around 38 minutes earlier than normal while those taking placebo fell asleep 13 minutes earlier.
Slovenian: Poleg tega so otroci, ki so jemali zdravilo Slenyto, zaspali približno 38 minut prej kot običajno, otroci, ki so jemali placebo, pa 13 minut prej.